NYSEArca - Nasdaq Real Time Price USD

The Consumer Discretionary Select Sector SPDR Fund (XLY)

200.44 +3.55 (+1.80%)
As of 3:28 PM EDT. Market Open.
Loading Chart for XLY
DELL
  • Previous Close 196.89
  • Open 200.51
  • Bid 200.69 x 1100
  • Ask 200.70 x 800
  • Day's Range 199.91 - 202.14
  • 52 Week Range 158.15 - 203.08
  • Volume 2,696,274
  • Avg. Volume 2,844,792
  • Net Assets 19.48B
  • NAV 196.98
  • PE Ratio (TTM) 31.30
  • Yield 0.75%
  • YTD Daily Total Return 10.81%
  • Beta (5Y Monthly) 1.29
  • Expense Ratio (net) 0.09%

The Advisor employs a replication strategy. The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Discretionary companies by the Global Industry Classification Standard (GICS®). It is non-diversified.

SPDR State Street Global Advisors

Fund Family

Consumer Cyclical

Fund Category

19.48B

Net Assets

1998-12-16

Inception Date

Performance Overview: XLY

View More

Trailing returns as of 10/31/2024. Category is Consumer Cyclical.

YTD Return

XLY
10.81%
Category
12.51%
 

1-Year Return

XLY
30.50%
Category
29.63%
 

3-Year Return

XLY
0.12%
Category
2.76%
 

People Also Watch

Holdings: XLY

View More

Top 10 Holdings (69.39% of Total Assets)

SymbolCompany% Assets
AMZN
Amazon.com, Inc. 22.07%
TSLA
Tesla, Inc. 14.70%
HD
The Home Depot, Inc. 8.14%
MCD
McDonald's Corporation 4.44%
LOW
Lowe's Companies, Inc. 4.27%
BKNG
Booking Holdings Inc. 3.91%
TJX
The TJX Companies, Inc. 3.68%
SBUX
Starbucks Corporation 3.06%
NKE
NIKE, Inc. 2.94%
CMG
Chipotle Mexican Grill, Inc. 2.18%

Sector Weightings

SectorXLY
Technology   0.75%
Industrials   0.40%
Real Estate   0.00%
Utilities   0.00%
Energy   0.00%
Healthcare   0.00%

Recent News: XLY

View More

Research Reports: XLY

View More
  • Biogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • BUY on regulatory advancements and higher guidance

    Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.

    Rating
    Price Target
     
  • U.S. stock indices are mostly in the red today, with investors perhaps

    U.S. stock indices are mostly in the red today, with investors perhaps experiencing a little 'green exhaustion' after the solid gains booked of late. Also of note, the meaningful news starts to hit the tape tomorrow with the release of the Fed minutes, so getting a little defensive in case the minutes include unwanted news is also defensible.

     

Related Tickers